Xoma Crumbles And Partner Rezolute Collapses On Failed Insulin Disease Drug
Summarize this article with:
BREAKING: ARK Invest Funds Obliterate All But One ETFXoma stock plummeted Thursday after its partner, Rezolute, scrapped the development of a hyperinsulinism treatment that failed in Phase 3 testing. In hyperinsulinism, the pancreas creates too much insulin, leading to dangerously low blood sugar. Rezolute's (RZLT) drug led to a 45% decrease in weekly hypoglycemia events. But that wasn't statistically significant compared with a 40% decline for the placebo… 11/07/2017 On Wednesday, Xoma got an upgrade for its IBD SmartSelect Composite Rating from 85 to 96. 11/07/2017 On Wednesday, Xoma got an upgrade for its IBD SmartSelect... Get instant access to exclusive stock lists, expert market analysis and powerful tools with 2 months of IBD Digital for only $20!Get market updates, educational videos, webinars, and stock analysis.Learn how you can make more money with IBD's investing tools, top-performing stock lists, and educational content.Information in Investor’s Business Daily is for informational and educational purposes only and should not be construed as an offer, recommendation, solicitation, or rating to buy or sell securities. The information has been obtained from sources we believe to be reliable, but we make no guarantee as to its accuracy, timeliness, or suitability, including with respect to information that appears in closed captioning. Historical investment performances are no indication or guarantee of future success or performance. Authors/presenters may own the stocks they discuss. We make no representations or warranties regarding the advisability of investing in any particular securities or utilizing any specific investment strategies. Information is subject to change without notice. For information on use of our services, please see our Terms of Use.*Real-time prices by Nasdaq Last Sale. Real-time quote and/or trade prices are not sourced from all markets. Ownership data provided by LSEG and Estimate data provided by FactSet.IBD, IBD Digital, IBD Live, IBD Weekly, Investor's Business Daily, Leaderboard, MarketDiem, MarketSurge and other marks are trademarks owned by Investor's Business Daily, LLC.©2025 Investor’s Business Daily, LLC.
All Rights Reserved.